Mutations within the rplD Gene of Linezolid-Nonsusceptible Streptococcus pneumoniae Strains Isolated in the United States

W. Dong, S. Chochua, L. McGee, D. Jackson, K. P. Klugman, J. E. Vidal

Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Respiratory Diseases Branch, Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Three invasive Streptococcus pneumoniae strains nonsusceptible to linezolid were isolated in the United States between 2001 and 2012 from the CDC’s Active Bacterial Core surveillance. Linezolid binds ribosomal proteins where structural changes within its target site may confer resistance. Our study identified mutations and deletions near the linezolid binding pocket of two of these strains within the rplD gene, which encodes ribosomal protein L4. Mutations in the 23S rRNA alleles or the rplV gene were not detected.

Linezolid was the first oxazolidinone to be licensed in the United States (in 2000) and marketed worldwide (1–3). Linezolid is approved by the U.S. Food and Drug Administration (FDA) for the treatment of complicated skin infections, meningitis, nosocomial pneumonia, endocarditis, sepsis, osteomyelitis, concurrent bacteremia, and bacteremia associated with community-acquired pneumonia (1, 2).

Linezolid blocks the assembly of a functional initiation complex for protein synthesis, thereby preventing mRNA translation. Other antibiotics that prevent mRNA translation include chloramphenicol, tetracycline, macrolides, and lincosamides. They allow the formation of an initiation complex but inhibit subsequent peptide elongation (3, 4).

The LEADER (Linezolid Experience and Accurate Determination of Resistance) program, which monitors linezolid-resistant clinical isolates, reports that, in the United States, linezolid-sensitive Streptococcus pneumoniae isolates have an MIC<sub>90</sub> of 1 μg/ml (5–9). Therefore, S. pneumoniae clinical strains with linezolid MICs of >1 μg/ml should be monitored and investigated for potential mechanisms of resistance. This is consistent with the Clinical and Laboratory Standards Institute (CLSI) breakpoint of 2 μg/ml (10).

The mechanisms of resistance to linezolid that have been described to date include target modification and use of a mobile cfr element (2, 8, 11). The linezolid target (the 50S subunit) is composed of 35 and 23S rRNAs and 36 riboproteins (L1 through L36). Linezolid-resistant strains present mutations in one or more alleles of the 23S RNA gene, decreasing the affinity of ribosomes for the drug (12). A clear correlation between the number of 23S RNA alleles mutated and increased linezolid resistance has been demonstrated (13, 14). The most frequently reported mutation in linezolid-resistant clinical isolates of staphylococci and enterococci occur by G-to-U substitution in the peptidyl transferase center of 23S RNA at position 2576 (2, 8). Additional mutations within the same 23S RNA gene have also been described (e.g., A2059G, C2190T, and G2447T) (15–17).

The cfr mobile element includes the cfr gene, which encodes a methyltransferase that methylates the 23S RNA at position A2503. This affects binding of linezolid to the 50S subunit (11, 18, 19). While carried by Staphylococcus aureus strains (20, 21) and recently described in Streptococcus suis (22), this mobile element has not been described in S. pneumoniae.

Only a few S. pneumoniae strains with reduced susceptibilities to linezolid have been isolated from disease cases (16, 23). For these strains, it was suggested that mutations in 23S rRNA genes and those encoding ribosomal proteins L4 and L22 confer linezolid resistance (16). However, direct evidence demonstrating deletions within the rplD gene of S. pneumoniae strain TN33388, encoding ribosomal protein L4, which is linked to reduced susceptibility to linezolid, was published by Wolter et al. (23). Strain TN33388 was identified through the Active Bacterial Core surveillance (ABCs), part of the Centers for Disease Control and Prevention’s (CDC’s) Emerging Infections Program.

In this study, the CDC Streptococcus laboratory identified two other additional S. pneumoniae strains (7828–04 and 2008227074) with reduced susceptibilities to linezolid. Overall, 3 of 45,099 pneumococci tested (≤1%) were isolated from invasive disease in the United States between 2001 and 2012 through the ABCs, and they showed reduced susceptibilities to linezolid (Table 1). Mutations within demonstrated linezolid targets were investigated in these two isolates.

Strain TN33388 from the CDC (for whom its mechanism of resistance to linezolid had been investigated), two serotype 19A linezolid-susceptible strains, and the reference S. pneumoniae strain R6 were utilized as controls (23). The MICs for linezolid, vancomycin, penicillin, amoxicillin, erythromycin, chloramphenicol, clindamycin, and tetracycline were determined using the broth microdilution methodology according to the CLSI (24). The linezolid-susceptible strains shown in Table 1 had linezolid MICs of 0.25 or 1 μg/ml, whereas linezolid-nonsusceptible strains had MICs of 4 μg/ml. The strains were susceptible to penicillin, vancomycin, amoxicillin, and tetracycline. Except for one strain (3084-03), they were also susceptible to clindamycin. Linezolid-nonsusceptible strains were resistant to chloramphenicol and erythromycin (Table 1).
To investigate the molecular mechanism of reduced susceptibility to linezolid, we amplified, purified, and sequenced the rplD gene (encoding the ribosomal protein L4), the rplV gene (encoding the ribosomal protein L22), and all four 23S rRNA alleles. The presence of the cfr gene in these linezolid-nonsusceptible strains was also sought.

For DNA extraction, S. pneumoniae strains were cultured on Trypticase soy agar (TSA) supplemented with 5% sheep blood and incubated overnight at 37°C in 5% CO2. Chromosomal DNA was then extracted by using the QIAamp DNA minikit (Qiagen, Inc., Valencia, CA) and the primers L4F (AAATCAGCAGTTAAAGCTGG) and L4R (GAGCTTTCA) for the rplD gene (encoding the ribosomal protein L4), the rplV gene (encoding the ribosomal protein L22), and all four 23S rRNA alleles. The sequences of the rplD gene of the linezolid-nonsusceptible strains had mutations and deletions within only the rplD gene (Table 1 and Fig. 1). Strain 2008227074 contained two mutations leading to the amino acid substitutions Q67R and R72G. These two mutations had not been described before in linezolid-nonsusceptible S. pneumoniae strains. Strain 7828-04 presented a 6-bp deletion (ΔW65R66) that was similar, but not identical, to that previously identified in strain TN33388 (23). The two linezolid-susceptible strains had a substitution (S20N) which was caused by a single-nucleotide change in position 59 (G59A) of the nucleotide sequence. S20N is apparently out of the linezolid binding pocket.

In conclusion, the 2 clinical isolates of S. pneumoniae with reduced susceptibilities to linezolid in the United States may account for the low mutation rates in its target and therefore the continued activity against S. pneumoniae (Table 1 and Fig. 1).

### Table 1: Phenotypic findings of S. pneumoniae strains with reduced susceptibilities to linezolid

<table>
<thead>
<tr>
<th>Strain (yr of isolation, state)</th>
<th>Serotype</th>
<th>L4 phenotype</th>
<th>MIC (µg/ml)*</th>
<th>Reference or source</th>
</tr>
</thead>
<tbody>
<tr>
<td>0566-02 (2001, GA)</td>
<td>19A</td>
<td>S20N</td>
<td>0.25 0.25 0.06 0.06 0.12 ≤2 0.12 ≤2</td>
<td>This study</td>
</tr>
<tr>
<td>3084-03 (2002, GA)</td>
<td>19A</td>
<td>S20N</td>
<td>1 0.25 0.12 0.06 0.25 ≤2 0.5 ≤2</td>
<td>This study</td>
</tr>
<tr>
<td>7828-04 (2004, CT)</td>
<td>014</td>
<td>ΔW65R66*</td>
<td>4 0.5 2 1 2 8 0.12 ≤2</td>
<td>This study</td>
</tr>
<tr>
<td>2008227074 (2007, NM)</td>
<td>09N</td>
<td>Q67R, R72G</td>
<td>4 0.25 ≤0.03 ≤0.03 1 &gt;8 0.06 ≤2</td>
<td>This study</td>
</tr>
<tr>
<td>TN33388 (2003, TN)</td>
<td>33F</td>
<td>ΔK68G69</td>
<td>4 0.25 ≤0.03 ≤0.03 1 8 0.25 ≤2</td>
<td>22</td>
</tr>
</tbody>
</table>

* L4, linezolid; VAN, vancomycin; PEN, penicillin; AMO, amoxicillin; ERY, erythromycin; CHL, chloramphenicol; CLI, clindamycin; TET, tetracycline. Current CLSI breakpoints: L4 susceptible (S), ≤2 µg/ml; VAN S, ≤1 µg/ml; PEN S, ≤2 µg/ml; AMO S, ≤0.25 µg/ml; ERY S, ≤0.25 µg/ml, and CHL R, ≥1 µg/ml; PEN R, ≥0.25 µg/ml; ERY R, ≥4 µg/ml; and AMO R, ≥8 µg/ml. MIC ranges were determined using the Etest (AB Biodisk, Solna, Sweden) and broth microdilution with the Clinical and Laboratory Standards Institute (CLSI) guidelines (26). △, Deletion.

FIG 1 Alignment of ribosomal protein L4 of linezolid-nonsusceptible isolates of S. pneumoniae and linezolid-susceptible strains. Mutations are shown in bold type. Dashes represent deletions, and identical sequences, in comparison to strain R6, are indicated by a straight line. Numbers underneath the specific amino acids (aa) represent the position in the R6 sequence.
pneumoniae strains. Similarly, a global study that utilized strains \((n = 636)\) isolated in 22 different countries showed susceptibility to linezolid in all \(S. pneumoniae\) strains \((31)\). Despite many years of exposure to the drug, the very low rate of linezolid resistance in pneumococci suggests that the fitness cost of resistance \((32)\) may be suppressing the successful dissemination of these strains in the pneumococcus.

ACKNOWLEDGMENTS
We are grateful for the contributions of members of the Centers for Disease Control and Prevention Active Bacterial Core surveillance/Emerging Infections Program Network. We also thank Magderie Klugman and Herbert P. Ludewick, Emory University, for their valuable assistance.

REFERENCES
